FNCH News and Press, Finch Therapeutics Group Inc. From 04/29/22

What to Know About Buying Penny Stocks Today With so much going on in the stock market right now, there is a lot for investors to know about trading penny stocks. To understand how to make money with penny stocks , investors need to have a thorough consideration of what is going on ...

GTY Technology (GTYH) +119% as investment firm agrees to pay 123% premium in taking the company private. Finch Therapeutics (FNCH) +63% as FDA lifts clinical hold on antibacterial drug. Zymeworks (ZYME) +47% on $10.50/share takeover bid. Lantheus Holdings (LNTH)&...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s the beginning of the end as we break down all of the biggest pre-market stock movers for Friday! Source: Eric Urquhart/Shutterstock.com News out of China, earnings, FDA updates, and more have stocks on t...

The clinical-stage biotech Finch Therapeutics (NASDAQ:FNCH) announced that the U.S. Food and Drug Administration (FDA) lifted the clinical hold on its investigational new drug (IND) application for experimental antibacterial drug, CP101. Finch (FNCH) shares have surged ~37% in the p...

SOMERVILLE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel...

Finch Therapeutics (NASDAQ:FNCH) said Tuesday it plans to reduce its workforce by ~20%. The move will allow FNCH to focus its financial resources on its wholly-owned programs - recurrent C. difficile infection and autism spectrum disorder development programs - and its work with Takeda i...

SOMERVILLE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel...

Gainers: Lexaria Bioscience (LEXX) +23%. Rite Aid (RAD) +14%. Inozyme Pharma (INZY) +12%. Finch Therapeutics (FNCH) +11%. Valneva (VALN) +9%. Losers: Protagonist Therapeutics (PTGX) -23%. Lixte Biotechnology (LIXT) -10%. Biofrontera (BFRI) ...

Finch Therapeutics press release (NASDAQ:FNCH): Q4 GAAP EPS of -$0.40. Revenue of $0.8M (-55.6% Y/Y). For further details see: Finch Therapeutics GAAP EPS of -$0.40, revenue of $0.8M

SOMERVILLE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel cla...